JIANGSU RECBIO TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9 CNY | -2.49% |
|
-1.64% | -17.13% |
ETFs positioned on Jiangsu Recbio Technology Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.05% | 4 M€ | -27.92% |
Jiangsu Recbio Technology Co Ltd is a China-based company mainly engaged in the research and development of vaccines. The Company has a portfolio of clinical-stage and pre-clinical stage vaccines, and its human papilloma virus (HPV) vaccine pipelines comprise of recombinant HPV 9-valent vaccine REC603, recombinant HPV 9-valent vaccines REC601 and REC602, recombinant HPV quadrivalent vaccine REC604a, and recombinant HPV 9-valent vaccine REC604b. The Company also involves in the development of Covid-19 vaccines. The Company mainly distributes products within domestic market.
Sector
Pharmaceuticals
Calendar
22/08/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
8.329
CNY
Average target price
13.79
CNY
Spread / Average Target
+65.54%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.13% | 551M | |
| -3.93% | 86.16B | |
| +2.76% | 40.17B | |
| -16.65% | 31.47B | |
| +54.44% | 25.24B | |
| -12.31% | 15.82B | |
| -9.12% | 11.96B | |
| -15.37% | 11.89B | |
| -42.56% | 11.61B | |
| +4.87% | 8.84B |
- Stock Market
- Equities
- 2179 Stock
- Funds and ETFs Jiangsu Recbio Technology Co., Ltd.
